EN Contact sales
bioseutica®, the 1st choice for food, pharma and feed ingredients
Rendering of protein structures in suspension

Lysozyme, egg white proteins and pancreatic enzymes from natural sources

Lysozyme for food, feed and pharma

Lysozyme hydrochloride from hen egg white in food, feed and API grades, for the natural preservation of cheese, wine and beer and for pharmaceutical use.

Explore lysozymeContact Sales

Specifications, certificates of analysis and regulatory documentation available on request.

Extraction, protein fractionation, bioseparation and purification of enzymes and proteins from hen egg white and from porcine and marine sources.

Processes
  • Extraction
  • Protein fractionation
  • Bioseparation
  • Purification
Sources
  • Hen egg white
  • Porcine
  • Marine

Three companies: production in the Netherlands and Canada, commercial and regulatory operations in Switzerland.

About the Group

bioseutica® B.V.bioseutica® SRL

Extraction and purification of egg-white proteins, including food and pharmaceutical-grade lysozyme.

  • Zeewolde, The Netherlands
  • Bastogne, Belgium

Neova Technologies Inc.

Bioseparation and protein fractionation of egg proteins and pancreatic enzymes.

Abbotsford, British Columbia, Canada

Fordras SA

Commercial company for the Group's pharmaceutical and food ingredients, active since 1983.

Lugano, Switzerland

Products

Natural-source proteins and enzymes, produced with solvent-free processes.

bioseutica® manufactures lysozyme, egg white proteins and pancreatic enzymes from natural sources, using solvent-free extraction and purification: lysozyme hydrochloride in food, feed and API grades; avidin, ovotransferrin and ovalbumin for research use (RUO) and diagnostics; proteases, including the marine trypsin AQUATRYP®, for nutrition, supplements, functional ingredients, topical applications and cell culture. Technical datasheets are available online; specifications, certificates of analysis and regulatory documentation on request.

All products

Industry Applications

Protein ingredients for food, nutrition, feed, pharmaceutical, diagnostic and personal care applications.

All industries

Our Business

Isolation of target proteins from complex natural raw materials, with their biological activity preserved.

Manufacturing process

  1. 01

    Source

    Hen egg white, porcine pancreas and marine raw materials from qualified, traceable suppliers.

  2. 02

    Solvent-free extraction

    Gentle processes that preserve the protein's native function.

  3. 03

    Purification

    Chromatographic and physical separation to a defined purity.

  4. 04

    Quality control and release

    Batch testing and documentation for food, API and reagent grades.

Contract manufacturing services

Supply, co-development and licensing of protein-based ingredients and processes.

  • Supply agreements

    Long-term, specification-controlled supply of standard grades.

  • Co-development and custom proteins

    Tailor-made preparations, scaled from bench to industrial production.

  • Licensing

    In- and out-licensing of patented processes, ingredients and assets.

Discuss a partnershipExplore our technology

Bench to pilot (up to 100 kg) to industrial scale. [N] patent families

Quality & Compliance

Certifications, regulatory status and inspection history for supplier qualification.

Certifications

  • GMP certificates, EU lysozyme plants
  • FSSC 22000
  • HACCP, North American plants
  • GDP, Swissmedic
  • Kosher and Halal (lysozyme)

Regulatory status

  • Lysozyme GRAS-affirmed in the US since 1998
  • EFSA opinion on lysozyme food enzyme (2023)
  • EFSA opinions on Trypsin VI and SE
  • Status by product and region on request

Inspections and memberships

  • FDA inspection, Zeewolde (2019)
  • Health Canada GMP inspection (2018)
  • Member of AMFEP, ETA and OENOPPIA
Request regulatory documents Certificates, specifications or a supplier questionnaire

Pipeline

Proprietary assets developed by the Group and available for licensing.

Asset available for licensing

Amcipatricin SPK-843

Semi-synthetic, water-soluble polyene antifungal in development for inhaled use against severe fungal infections.

View the asset sheet Discuss licensing
Indication
Severe fungal infections in cystic fibrosis or immunocompromised patients
Stage
[Development stage]
IP
Patent pending
Seeking
Development and commercial partners

Development stage Phase I

  1. Discovery
  2. Preclinical
  3. Phase I
  4. Phase II
  5. Phase III
  6. Registration

Insights & Updates

Regulatory updates, application notes and scientific background on our proteins.

All news

Contact us

Enquiries on products, documentation, distribution and partnerships are handled by the relevant specialist team.

  • Response within two business days
    From a product specialist.
  • NDA available
    Before any confidential technical discussion.
  • Documentation
    Specifications, certificates of analysis and regulatory statements.

For job applications, see Careers.

Start a conversation

We use your details to answer this request, as described in our privacy policy.

Our history and footprint

Milestones since 1947, production and extraction sites, and the countries we serve. Select a figure.

  1. Rodolfo Ferrari and Carlo Callerio found the Italian company SPA (Società Prodotti Antibiotici) to manufacture penicillin and lysozyme.

  2. SPA and Sir Alexander Fleming collaborate to develop large-scale production of penicillin and lysozyme.

  3. SPA establishes the first industrial-scale lysozyme plant at NIVE in Nunspeet, The Netherlands.

  4. SPA establishes Fordras SA in Lugano, Switzerland, for worldwide sales of lysozyme API and for R&D.

  5. Canadian company Neova Technologies starts lysozyme production in Zeewolde, The Netherlands, and begins working with Kaken on the new polyene amcipatricin.

  6. Fordras SA is spun off from SPA; LMC B.V. starts production of lysozyme API and of the amcipatricin molecule.

  7. Fordras SA and Neova Technologies Inc. merge under bioseutica® B.V.

  8. Egg white extraction is consolidated in The Netherlands, pancreatic enzymes in Canada.

  9. New products are developed: NA2R® (2014), Entegard® (2018) and AVIFORT™ (2018).

  10. Acquisition of Belovo, Belgium, from BNL Food Group.

  11. bioseutica® Fordras SA launches its first consumer product, LYSOGUARD immune®.

  12. bioseutica® opens a new lysozyme plant in Ospel, The Netherlands, and celebrates 100 years of lysozyme in Lugano with international guests and customers.

  13. bioseutica® establishes new production plants in Asia.

Production sites

Manufacturing in Europe, Canada and Asia.

  • Zeewolde, The Netherlandsbioseutica® B.V., lysozyme and egg white proteins
  • Ospel, The NetherlandsLysozyme plant, opened in 2022
  • Bastogne, Belgiumbioseutica® SRL (formerly Belovo), acquired in 2017
  • Abbotsford, CanadaNeova Technologies Inc., egg proteins and pancreatic enzymes
  • [Asia, plants established in 2024][Town, country, activity]
  • [Production site 6][Town, country, activity]
  • [Production site 7][Town, country, activity]

Extraction sites

Egg white extraction in The Netherlands, pancreatic enzymes in Canada (since 2011).

  • [Zeewolde], The NetherlandsHen egg white [site to be confirmed]
  • Abbotsford, CanadaPorcine pancreas: pancreatic enzymes
  • [Extraction site][Marine raw materials]

Countries served

Customers in 30 countries. [Sample list, to be confirmed]

  • Europe 18

    • Netherlands
    • Belgium
    • Germany
    • France
    • Italy
    • Spain
    • Portugal
    • Switzerland
    • Austria
    • United Kingdom
    • Ireland
    • Denmark
    • Sweden
    • Norway
    • Finland
    • Poland
    • Czechia
    • Greece

  • Americas 6

    • United States
    • Canada
    • Mexico
    • Brazil
    • Argentina
    • Chile

  • Asia and Pacific 5

    • Japan
    • South Korea
    • China
    • India
    • Australia

  • Africa 1

    • South Africa